{
    "clinical_study": {
        "@rank": "112497", 
        "arm_group": [
            {
                "arm_group_label": "Group 1", 
                "arm_group_type": "Experimental", 
                "description": "End Stage Renal Diseas (ESRD) requiring hemodialysis"
            }, 
            {
                "arm_group_label": "Group 2", 
                "arm_group_type": "Experimental", 
                "description": "Normal renal function (eGFR >or = 80mL/min/1.73m^2)"
            }, 
            {
                "arm_group_label": "Group 3", 
                "arm_group_type": "Experimental", 
                "description": "Mild decrease in GFR (eGFR 60-79 mL/min/1.73m^2)"
            }, 
            {
                "arm_group_label": "Group 4", 
                "arm_group_type": "Experimental", 
                "description": "Moderate decrease in GFR (eGFR 30-59 mL/min/1.73m^2)"
            }, 
            {
                "arm_group_label": "Group 5", 
                "arm_group_type": "Experimental", 
                "description": "Severe decrease in GFR (eGFR 15-29 mL/min/1.73m^2)"
            }, 
            {
                "arm_group_label": "Group 6", 
                "arm_group_type": "Experimental", 
                "description": "Normal renal function (eGFR >or = 80mL/min/1.73m^2)"
            }
        ], 
        "brief_summary": {
            "textblock": "A phase 1, open-label study in subjects with normal renal function and subjects with various\n      degrees of renal insufficiency, including patients with end-stage renal disease (ESRD)\n      requiring hemodialysis. The primary objective is to evaluate the single-dose PK of AMG 423\n      in subjects with various degrees of renal insufficiency, including patients with end-stage\n      renal disease requiring hemodialysis."
        }, 
        "brief_title": "Pharmacokinetics Study of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal Insufficiency", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Heart Failure", 
        "condition_browse": {
            "mesh_term": [
                "Heart Failure", 
                "Renal Insufficiency"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men or women \u226518 years of age\n\n          -  Laboratory test values (clinical chemistry and hematology)within normal limits,\n             (other than test values out of the normal range for subjects with CKD [groups 1 and 3\n             through 5]), or clinically acceptable to the investigator and sponsor at screening\n             and day -3\n\n          -  Free of any clinically significant disease or condition(s) (other than that\n             consistent with CKD for subjects in groups 1 and 3 through 5) that require a\n             physician's care and/or would interfere with the evaluations, procedures, or\n             participation in the study per the investigator's discretion;\n\n        Exclusion Criteria:\n\n          -  Subjects whose second MDRD eGFR result during the screening period is not within 10%\n             of the first eGFR result\n\n          -  Subjects who have received a functioning renal transplant within the past year\n\n          -  Subjects with ESRD who do not have a functioning hemodialysis access\n\n          -  Subjects with hemodynamic instability during hemodialysis\n\n          -  Subjects whose renal insufficiency is due to active autoimmune renal disease\n\n          -  Subjects with renal insufficiency or ESRD requiring hemodialysis and Troponin I >\n             upper limit of normal (ULN) at screening or day -3\n\n          -  Subjects with history of heart disease or unstable angina within the last 3 months\n\n          -  Subjects with uncontrolled diabetes (Hb1Ac > 8%) and/or subjects who are able but\n             unwilling to adhere to the required fasting intervals"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "13", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01737866", 
            "org_study_id": "20080676"
        }, 
        "intervention": {
            "arm_group_label": [
                "Group 1", 
                "Group 2", 
                "Group 3", 
                "Group 4", 
                "Group 5", 
                "Group 6"
            ], 
            "description": "omecamtiv mecarbil", 
            "intervention_name": "AMG 423", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Heart, Failure, Renal, Insufficiency, Cardiac, Kidney, Hemodialysis, Impairment, omecamtiv mecarbil, cardiac myosin activator, CK-1827452", 
        "lastchanged_date": "August 9, 2013", 
        "link": {
            "description": "AmgenTrials clinical trials website", 
            "url": "http://www.amgentrials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Orlando", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "32809"
                }, 
                "name": "Research Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "6", 
        "official_title": "An Open-label, Single-dose Study of the Safety, Tolerability, and Pharmacokinetics of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal Insufficiency and Effect of Hemodialysis on AMG 423 Pharmacokinetics", 
        "overall_official": {
            "affiliation": "Amgen", 
            "last_name": "MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Part A and Part B: Total AMG 423 pharmacokinetic parameters including area under the plasma concentration time curve (AUC) from time 0 to the time of the last quantifiable sample (AUC0-t) and maximum observed plasma concentration after dosing (Cmax).", 
            "measure": "AMG 423 Pharmacokinetic Parameters", 
            "safety_issue": "No", 
            "time_frame": "Twenty time points, up to eight days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01737866"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Total AMG 423 pharmacokinetic parameters including but not limited to terminal phase half life (t1/2) and time of maximum AMG 423 plasma concentration (tmax), AUC from time 0 to infinity (AUCinf) and apparent plasma clearance (CL/F) for Part A and Part B;", 
                "measure": "Other Total AMG 423 PK Parameters", 
                "safety_issue": "No", 
                "time_frame": "Twenty time points, up to eight days"
            }, 
            {
                "description": "AMG 423 dialysis clearance (CLd) for ESRD subjects in Part A;", 
                "measure": "AMG 423 Dialysis Clearance", 
                "safety_issue": "No", 
                "time_frame": "Hours 4, 5, 6, 7 & 8 post-dose"
            }, 
            {
                "description": "AMG 423 metabolites (M3 and M4) pharmacokinetic parameters including but not limited to AUC0-t, AUCinf, AUC metabolite to parent ratios, Cmax, tmax and t1/2, if appropriate.", 
                "measure": "AMG 423 Metabolites", 
                "safety_issue": "No", 
                "time_frame": "Twenty time points, up to eight days"
            }, 
            {
                "description": "Secondary safety endpoints are subject incidence of adverse events and clinically significant changes in vital signs, physical examinations, clinical laboratory tests and ECGs.", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 46 days, including a 28 day screening period"
            }
        ], 
        "source": "Amgen", 
        "sponsors": {
            "collaborator": {
                "agency": "Cytokinetics", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}